Presentation of underglycosylated mucin 1 in pancreatic adenocarcinoma (PDAC) at early stages.

Su-Tang Lo, Pamela Pantazopouos, Zdravka Medarova, Anna Moore

Open access · greenAbstract read

In one paragraph

Article in American journal of cancer research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it

0cells of the map it votes in

4citing papers in PubMed

0.5field-weighted citation impact, top 27% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

Overview and Future Perspectives on Tumor-Targeted Positron Emission Tomography and Fluorescence Imaging of Pancreatic Cancer in the Era of Neoadjuvant Therapy.Cancers · 2021
Review
Characterization of Cell Glycocalyx with Mass Spectrometry Methods.Cells · 2019
Review
Nerves and Pancreatic Cancer: New Insights into a Dangerous Relationship.Cancers · 2019
Review
Mucins in pancreatic cancer: biological role, implications in carcinogenesis and applications in diagnosis and therapy.American journal of cancer research · 2017
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Su-Tang LoMolecular Imaging Laboratory, MGH/MIT/HMS Athinoula A Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical SchoolCharlestown, MA 02129, USA; Current address: Advanced Imaging Research Center, UT Southwestern Medical CenterDallas, TX 75390, USA.

Pamela PantazopouosMolecular Imaging Laboratory, MGH/MIT/HMS Athinoula A Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School Charlestown, MA 02129, USA.

Zdravka MedarovaMolecular Imaging Laboratory, MGH/MIT/HMS Athinoula A Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School Charlestown, MA 02129, USA.

Anna MooreMolecular Imaging Laboratory, MGH/MIT/HMS Athinoula A Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School Charlestown, MA 02129, USA.

Harvard University Press · US

Funding

Predictive Cancer Diagnostics and Therapy ResponseR01CA135650 · NCI · MICHIGAN STATE UNIVERSITY · PI MEDAROVA, ZDRAVKA O, MOORE, ANNA · 2008 to 2018

$4.6M

MicroRNA Therapy for Lymph Node Metastatic Breast CancerR01CA163461 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI MEDAROVA, ZDRAVKA O · 2012 to 2016

$1.9M

NCI NIH HHS R01 CA135650NCI NIH HHS R01 CA163461

6 · The paper itself

Abstract

Underglycosylated mucin 1 antigen (uMUC1) is a proven biomarker of cancer progression relevant to many malignancies including pancreatic ductal adenocarcinoma (PDAC). However, while ample evidence exists of the expression of total MUC1, little is known about the abundance of the underglycolsylated form of the antigen and its significance in disease progression. Such knowledge is important because the underglycosylated form of MUC1 is intimately linked to metastatic potential. Here, we investigated the expression uMUC1 at various stages of PDAC including pancreatic intraepithelial neoplasia (PanIN). Immunohistochemical analysis was performed on human tissue microarrays (TMAs) containing PDAC and PanIN using monoclonal antibody specific to uMUC1. uMUC1 expression was analyzed by a traditional pathological scoring system and using automatic imaging analysis software. Our results demonstrated low uMUC1 abundance in PanIN lesions and a transient increase in antigen availability in stage I PDAC, followed by decreased expression in later stages of the disease. An additional finding was that there was intermediate expression of uMUC1 in adjacent normal tissues from PDAC irrespective of the stage. These studies suggest the intriguing possibility that a pro-metastatic uMUC1 expression signature may appear at early stages of PDAC, providing an additional clue about the aggressive nature of pancreatic cancer.

Indexed as

immunohistochemistryPancreatic cancertumor antigenunderglycosylated mucin 1

Identifiers

PMID27725904

PMCPMC5043108

OpenAlexW2552622855

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.